Introduction
Bufalin, which is extracted from the body covering of the Bufo bufo gargarizans Cantor, is a main active component of a traditional Chinese medicine (Chansu). 1 Bufalin has multi-target antitumor effect in a range of tumors, such as hepatocellular carcinomas, 2 colorectal cancer, 3 leukemia, 4 gastric cancer, 5 and osteosarcoma. 6 Preceding findings have revealed that the anticancer activity of bufalin could be attributed to its prevention submit your manuscript | www.dovepress.com
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Yang et al of cell proliferation, instruction of apoptosis, disturbance of the cell cycle, and modulation of the immune response. [7] [8] [9] Earlier study of ours revealed that bufalin had convincing anticancer growth and reduced the metastatic potentials in the human hepatocellular carcinoma-transplanted tumor model, and the fundamental mechanism was in part mediated by the signaling pathway of the Akt-GSK3β-β-catenin-Ecadherin. 10, 11 These results indicated that bufalin might be a purposeful constituent for cancer treatment. However, there was not much known about the distribution of bufalin in vivo, especially in a variety of tumors. Moreover, detection of bufalin and its metabolites was difficult in vivo.
Positron emission tomography (PET) is a noninvasive imaging method, which has been applied for clinical practice in many areas. 12 As a useful tool for imaging and calculating cell and molecular procedures in the body, PET has vast probability to enlarge our knowledge of the pathophysiology of tumors' diagnosis and assist the progress of anticancer drugs. 13 A number of antitumor drugs have been labeled with radionuclides successfully as imaging tracers for PET explorations, such as hormones, antibodies, kinase inhibitors, and other anticancer substances. [14] [15] [16] It is not surprising that the role of such technology in hastening anticancer drug events is approved in a crucial trial initiative by the US Food and Drug Administration (FDA). 17 The initial concept of microdosing of a drug has been presented applying radiolabeled drugs in conjunction with PET to attain preliminary data about distribution, pharmacokinetics, and tumor targets at an earliest stage of drug development. 18 PET is currently one of the most helpful noninvasive in vivo imaging techniques for the investigation of drug pharmacokinetics.
The purpose of this research was to evaluate the distributions, pharmacokinetics, and tumor-targeting performance of the potential anticancer drug bufalin in nude mice bearing with hepatocellular carcinomas. The evidences from the present imaging study could promote prospective investigation and be applied to monitor bufalin therapy efficacy in mice and future clinical practices.
Methods
general information
The reagents in the experiment were of analytical grade without additional refinement, unless specified otherwise. Bufalin (purity .98%) was obtained from Baoji Herbest Bio-Tech Co., Ltd (Baoji, People's Republic of China). 18 F-fluoride was received from a cyclotron (HM20; Sumitomo Heavy Industries, Ltd, Tokyo, Japan) situated in the Jiangsu Institute of Nuclear Medicine by proton irradiation of 18 O-enriched water. A high-performance liquid chromatography (HPLC) system (Waters, Milford, MA, USA) supplied with a Waters 2998 photodiode array (PDA) detector and a tetramethylammonium solid-phase extraction column (250×10 mm, 5 μm; Waters) was needed for [ 18 F]fluoroethyl refinement. The rate of flow was 3 mL/min, and the mobile phase started from 95% dissolvent A (0.1% trifluoroacetic acid in water) and 5% dissolvent B (0.1% trifluoroacetic acid in methanol; 0-2 min), and it was progressively shifted to 30% dissolvent A and 70% dissolvent B at 35 min. The ultraviolet absorbance was observed at 280 nm, and the ultraviolet spectrum was tested with the PDA detector.
Analytical HPLC was carried out in Waters Breeze System with a YMC-Pack Pro-C18 RS column (5 μm, 10×250 mm; Waters); the compound was controlled by using a Cd (Te) detector. The flow rate was 1 mL/min. The isocratic mobile phase was 0.05 mol/L phosphate-buffered saline (PBS; pH =7.0).
A micro-PET equipment (Inveon; Siemens Co., Knoxville, TN, USA) and a fluorescence microscope (X51; Olympus Corporation, Tokyo, Japan) were applied. The animal tests in this research were carried out by the Shanghai Medical Experimental Animal Care Committee. 
cell culture
The SMMC-7721 and HepG2 human hepatoma cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, People's Republic of China). Both cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) added with 10% fetal bovine serum (FBS) in a moisten atmosphere of 95% air and 5% CO 2 at 37°C. The two cell lines were used to establish the models. were injected subcutaneously into the left abdomen area of nude mice. When the subcutaneous tumors proliferated to almost 3 cm in width (~5 weeks after injection), they were removed and cut into small pieces of equal volume (1.5-2×2×2 mm 3 ) and then these slices were placed into the sterile saline solution.
Establishment of metastatic orthotopic tumor model
For the following liver orthotopic transplantation of above tumor slices, all the surgical procedures were performed under general anesthesia using intraperitoneal injection of 3% pelltobarbitalum natricum (45 mg/kg; Sigma-Aldrich Co., St Louis, MO, USA). Once anesthetized, the male BALB/c nude mice were fixed on an experimental board in a supine position. An 8-mm transverse incision was made below the left last rib margin, following sterilization of the area with 0.5% iodophor, which was perpendicular to the median line and was 1-1.5 cm long. The right liver lobes were carefully pulled out of the abdominal cavity with a sterile cotton swab. The smaller pieces of tumor (1.5-2×2×2 mm 3 ) were put into the right liver lobes at a depth of 3.5 mm using the surgery forceps. The tumor tissues were fixed in the right liver lobes with a plus 6-0 suture line. A small piece of sterile gauze was placed on the injection site, and light pressure was applied for 1 min to prevent bleeding and spilling. The skin was then sterilized with 70.5% iodophor, and the wound was sutured with a plus 5-0 suture line. 18 F]fluoroethyl bufalin was synthesized according to the reference for fluoroethyl bufalin. The details are as follows (Scheme 1). A Schlenk tube (10 mL) equipped with a magnetic stir bar was charged with NaH (50.0 mg, 1.3 mmol, 60% in mineral oil) and dry N,N-dimethylformamide (DMF; 1 mL) under N 2 . The mixture was cooled to 0°C and then bufalin (50.0 mg, 0.13 mmol) was added. After the mixture was stirred for 15 min, 2-bromofluoroethane (45 μL, 0.61 mmol) was added via syringe. After the reaction proceeded for 24 h at 20°C, the resulting solution was poured into ice water (10 mL) and then extracted by CH 2 Cl 2 (3×10 mL). The combined organic phase was dried over Na 2 SO 4 and concentrated under vacuo. The resulting residue was purified by silica gel flash column chromatography using petroleum ether:ethyl acetate (1/1) as eluent. The product fluoroethyl bufalin was obtained as a colorless solid (28.3 mg, 50%) - (10-12 mg) and Kryptofix 222 (1-2 mg) was put in a brown container. The reaction mixture was dried by helium gas flow and heated at 105°C for 10 min. Afterward, the reaction mixture was put into anhydrous acetonitrile (2 mL) and heated to 105°C under helium gas flow to remove water. The remainder was added into a solution of 1,2-bis(tosyloxy)ethane (10 mg) in anhydrous acetonitrile (1 mL). The reaction vial was sealed and heated at 90°C for 10 min. Then the reaction mixture was cooled down and anhydrous ether (8 mL) was added. The intermediate 18 F-CH 2 CH 2 OTs could be obtained after the mixture was dried with nitrogen flow.
18 F-CH 2 CH 2 OTs achieved above was redissolved in acetonitrile (1 mL) and was added into a solution of bufalin (20 mg, 0.3 μmol) in DMF (0.5 mL). The reaction was conducted at 110°C for 20 min until most of the 18 F-CH 2 CH 2 OTs had reacted with bufalin (detected by radio-thin layer chromatography [TLC], acetonitrile 95%). The final purification was completed through C18 reversed-phase chromatography (the testing method was installed for radioactivity, and the ultraviolet spectrophotometer absorbance was set at a wavelength of 280 nm). HPLC segments encompassing radioactivity were associated and dried up with a stream of argon to eliminate the acetonitrile. The in vitro stabilities of freshly prepared [
18 F]fluoroethyl bufalin were achieved respectively in PBS (0.1 mol/L, pH =7.2) and mouse serum at different periods (0-8 h) in a water bath at 37°C.
Biodistribution studies
The biodistribution of [ 18 F]fluoroethyl bufalin was studied in BALB/c nu/nu mice (20-22 g, 4 weeks old). Fifteen mice were used for intravenous injection. For intravenous administration, [ 
Pharmacokinetic studies
For pharmacokinetics studies, [ 18 F]fluoroethyl bufalin (7.4 MBq, 0.2 mL) was injected into the six ICR mice by intravenous injection through the caudal vein. An array of blood samples (10 μL) was accumulated in blood collection tubes by pinching the tail with a syringe at 3, 5, 10, 20, 30, 40, 60, 120, 240, 360, 480, and 600 min post injection (pi). The radioactivity of blood samples was evaluated and calculated as %ID/g. The radioactivity was displayed as a function of time. Meanwhile, pharmacokinetics parameters were counted through the pharmacokinetic calculation program (Drug And Statistics, version 2.1.1; Mathematical Pharmacology Professional Committee of China, Beijing, People's Republic of China). Pharmacokinetic equation was utilized to match the curve:
where C is the blood value of the [ major organs and tissues was got from average pixel values within the ROI level. After that, the data were translated to megabecquerel per milliliter per minute by the standardization factors measured in the Inveon PET equipment. The data were split by the radioactivity to get (presuming an organizational density of 1 g/mL) a %ID/g ROI image.
statistical analysis
The information was showed in the forms of mean ± SD and evaluated by SPSS v.22.0 software.
Results
radiosynthesis of [ 18 F]fluoroethyl bufalin
The conjugation of bufalin to 18 F-CH 2 CH 2 OTs occurred in this chemical, which is presented in Figure 1A . The product was purified by a reversed phase HPLC system. The chemical and radiochemical purities of [
18 F]fluoroethyl bufalin were 99%±0.18% (the consistent retention time =17.86 min, three times repetition). The purity and character of [ In vitro stability 
Biodistribution studies
The biodistribution of the [ 18 F]fluoroethyl bufalin was conducted in nude mice bearing SMMC-7721 and HepG2 tumors; the findings are shown in Table 1 and Figure 3 .
In SMMC-7721 hepatocellular carcinoma-bearing mice ( Figure 3A) , tumor uptake of 2.31%±0.71%ID/g was observed at 45 min pi and then it was increased slowly to 4.63%±0.94%ID/g at 2 h and decreased to 4.24%±0.86%ID/g at 4 h after injection. The results indicated that [
18 F]fluoroethyl bufalin in the liver was significantly higher than other organs, which reached 15.79%±0.73%ID/g at 45 min and then declined to 11.46%±3.3%ID/g at 2 h. Till 4 h, there was still an intense accumulation of 7.51%±1.17%ID/g. Activity accumulation in the kidneys decreased slowly from 7.17%±0.34%ID/g (45 min) to 3.21%±0.57%ID/g (2 h) after injection because of the excretion of the tracer into the urinary bladder. Blood CL fell rather promptly over time and presented low blood activity (1.82%±0.22%ID/g) at 2 h after injection.
In HepG2 hepatocellular carcinoma-bearing mice ( Figure 3B ), tumor uptake (2.59%±0.64%ID/g) was observed at 45 min pi and then increased slowly to 4.69%±0.92%ID/g and declined to 4.27%±0.50%ID/g at 2 and 4 h pi. These results indicated that [ 18 F]fluoroethyl bufalin uptake in liver was significantly higher than other organs, which reached 19.74%±0.28%ID/g at 45 min and then declined to 10.46%±0.44%ID/g at 2 h. At 4 h, there was still an intensity accumulation of 7.51%±1.17%ID/g. Activity accumulation in the kidneys decreased slowly from 45 min (7.17%±0.34%ID/g) to 2 h (3.21%±0.57%ID/g) after injection because of the excretion of the tracer into the urinary bladder. Blood CL fell rather promptly over time and presented low blood activity (1.85%±0.37%ID/g) in 2 h after injection.
The tracer uptake accumulated in the SMMC-7721 tumors, HepG2 tumors, and the major tissues. The uptake of [ 18 F]fluoroethyl bufalin in the liver was considerably higher than that in other tissues, for instance, the lung, stomach, spleen, and intestine at three time points. Rapid body CL from the circulation was mostly by the hepatic and renal pathways. Table 2 shows the pharmacokinetic parameters, attained by the pharmacokinetic calculation program. Micro-PeT images in sMMc-7721 and HepG2 tumor-bearing nude mice Radioactivity uptake of SMMC-7721 tumor was detected started at 5 min pi. As shown in Figure 6A , SMMC-7721 tumor uptake remained steady over time (2.96±0.75, 4.38±0.37, 4.70±0.29, 3.63±0.94, 3.24±0.86, and 2.48%±0.57%ID/g at 5 min, 35 min, 55 min, 2 h, 4 h, and 6 h pi, respectively). The liver uptake reached a peak (30.15%±3.05%ID/g) at 5 min pi and then declined to 15.83%±2.75%ID/g at 60 min pi. Tracer uptake in the heart, lung, and other organs also correlated well with the distribution results. An appreciable radioactivity accumulation in the bladder (33.14%±5.81%ID/g) was noticed at 120 min pi.
Pharmacokinetic studies
Radioactivity uptake of HepG2 tumor was also detected starting at 5 min pi. As shown in Figure 6B , HepG2 tumor uptake remained steady over time (2.59±0.64, 3.19±0.37, 4.44±0.69, 4.18±0.99, and 2.75%±0.62%ID/g at 5 min, 35 min, 55 min, 2 h, 4 h, and 6 h pi, respectively), corroborating 
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Yang et al the distribution results. The liver uptake reached a peak (39.84%±2.77%ID/g) at 5 min pi and then declined to 5.42%±1.27%ID/g at 60 min pi. Tracer uptake in the heart, lung, and other organs also correlated well with the distribution results. An appreciable radioactivity accumulation in the bladder (15.75%±1.9%ID/g) was noticed at 120 min pi. In the course of the initial part of this research, noticeable liver uptake was calculated, which suggests that hepatic metabolism was through the main excretory system. Elimination was also through the renal system, because of the marked CL to 
Discussion
In this study, [ 18 F]fluoroethyl bufalin was prepared successfully and proved to be stable in mouse serum. These properties warranted its in vivo PET imaging. From the tissue biodistribution studies, it was found that high uptake of [ 18 F]fluoroethyl bufalin was detected in the liver which would be due to high lipophilic property and other possible mechanisms of bufalin in vivo.
To better interpret PET imaging results, first we have to understand bufalin and its possible tumor treatment mechanism. It is known that cytochrome P450 3A4 (CYP3A4), a member of the cytochrome P450 mixed-function oxidase system, is one of the most significant enzymes involved in the metabolism of drugs in the body. CYP3A4 accounts for ~40% of the total cytochrome P450 in human liver microsomes and metabolizes .50% of the clinically used drugs. 19 Earlier research has also shown that bufalin had a modest but significant inhibition of CYP3A4 enzyme both in vitro and in vivo. 20 As a result, the high CYP3A4 enzyme metabolic capability in liver would be a probable explanation for the extremely high concentration of bufalin and [
18 F]fluoroethyl bufalin in liver. Additional risk would arise when the drug involved has a narrow therapeutic index, and further experiments are required to be carried out to determine whether bufalin could be metabolized by the liver system or whether its metabolites could inhibit the CYP3A4 enzyme.
Previous study demonstrated that bufalin inhibited the proliferation of SMMC-7721 and HepG2 human hepatocellular carcinoma cell lines in a dose-dependent and timedependent manner and therefore would induce G2/M phase cell cycle arrest, 21 induce the proteins for the mitochondriamediated apoptosis, 22 and inhibit the AKT/GSK3 beta/betacatenin/E-cadherin signaling pathway. 11 Moreover, bufalin reduced the proliferation of HepG2 and SMMC-7721 hepatocellular carcinoma cells, which was relevant to the expression of Na + /K + -ATPase α3, 23 because the protein expression of Na + /K + -ATPase α3 was at the same level in SMMC-7721 and HepG2 cells. 23, 24 This information can also support that tumor uptake of [ 18 F]fluoroethyl bufalin in SMMC-7721 and HepG2 tumor-bearing mice was similar in tissue distribution and PET imaging studies. The expression of Na + /K + -ATPase may be the reason of the drug uptake in tumor, and the mechanism needs to be further studied.
Interestingly, as observed in Figure 3 , differences were observed in concentration-time curves of [ 18 F]fluoroethyl bufalin. The AUC 0-t of double peaks suggested that enterohepatic recirculation might have occurred. 25 The double-peak phenomenon reported here was in agreement with previous reports. 26 Previous pharmacokinetic research presented an analogous phenomenon in rats. 27 It is known that drug absorption is a complicated course. The pharmacokinetic results manifest that [
18 F]fluoroethyl bufalin may be through potential interaction. More detailed pharmacokinetic research is needed to reveal the mechanism of the double-peak phenomenon.
These results of the imaging examination disclosed that [ ]fluoroethyl bufalin was trapped in the liver. Some studies suggested that the intestine, liver, and kidney might be the major distributive organs of bufalin in vivo after oral administration. 25 In this study, however, we found that the liver was actually the major accumulated site for this drug, while kidneys transmitted this drug to the urinary bladder quickly, which could account for high accumulation of the drug in mice bladders. A previous study had shown that bufalin prevented the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases. 28 Combined with our study, it is suggested that bufalin may be a promising therapeutic agent for bladder disease.
Conclusion
In the present research, we coupled bufalin with 18 F through the labeling intermediate 18 F]fluoroethyl bufalin temporarily accumulated in the liver and was excreted mainly through both hepatic pathway and renal pathway. There was moderate uptake of [ 18 F]fluoroethyl bufalin in two HCC tumors. Long-term accumulation of the tracer was not found in the organs. These results not only were helpful for the understanding of in vivo behavior of bufalin in clinical practices but also provided scientific information for monitoring bufalin therapy efficacy.
